The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    June 2020

  • Pages
    306

  • View Count
    3320

Example Insights

Live-Biotherapeutic-Products-and-Microbiome-Contract-Manufacturing-Market-Context Live-Biotherapeutic-Products-and-Microbiome-Contract-Manufacturing-Market-Pipeline Live-Biotherapeutic-Products-and-Microbiome-Contract-Manufacturing-Market-List-of-CMOs
Live-Biotherapeutic-Products-and-Microbiome-Contract-Manufacturing-Market-Global-regions Microbiome-manufacturing-developers-likely-partners Microbiome-manufacturing-regional-landscape
Live-Biotherapeutic-Products-and-Microbiome-Contract-Manufacturing-Market-Global-Production-Capacity Live-Biotherapeutic-Products-and-Microbiome-Contract-Manufacturing-Market-Forecast Live-Biotherapeutic-Products-and-Microbiome-Contract-Manufacturing-Market-geographical-regions

 

Overview

I believe that a lot of start-ups have entered the market, however, only a few companies have established their own facilities to manufacture microbiome-based products. This is primarily due to the fact that the cost of establishing an LBP production facility is high, and therefore, requires significant capital investment. As a result, companies have demonstrated preference to outsource manufacturing operations

-Vice President, Sales and Business Development, a US based Small-sized Company

Harnessing the naturally evolved, medicinal functions of gut bacteria in order to achieve desired clinical outcomes / benefits is the core principle behind the rapidly growing field of microbiome therapeutics. In fact, in recent years, promising insights from microbiome focused research has been the cause of much enthusiasm within the medical science community, offering a novel perspective related to personalized medicine. This particular class of products exists at the interface of naturopathic remedies (considering the active substances that are currently used) and clinically validated interventions, having demonstrated the ability to offer legitimate, quantifiable clinical benefits. Around 200 companies, including both private and public stakeholders, claim to be currently engaged in developing microbiome-based therapies for the treatment of a wide range of diseases. Several large pharmaceutical companies have also demonstrated interest in partnering with early-stage innovators in this domain. Having said that, most such initiatives are either still in the preclinical stages or early phase clinical trials. There are a few microbiome-based product candidates in phase II/III trials, which are anticipated to drive the market’s growth in the short-mid term. According to our estimates, the microbiome-based therapeutics market is projected to be worth over USD 2.1 billion by 2030, growing at an annualized rate of over 38%.

Despite the evident increase in interest in this field, manufacturing live microbial therapeutics remains a largely unaddressed area of concern. In fact, experts believe that the lack of sufficient manufacturing capacity is one of the major impediments to the commercialization of such products. Other challenges include absence of the required industry standards related to manufacturing live biotherapeutics, reproducibility (batch-to-batch consistency) related concerns, lack of expertise and infrastructure to handle anaerobic microbial strains, scaling up existing manufacturing protocols, intellectual property related issues (existing patent law prohibits patenting live organisms and naturally occurring materials) and uncertainties related to regulatory review and product approval. Owing to the aforementioned reasons and several others, such as need for specialized facilities, equipment and operational expertise, innovator companies have begun relying on contract manufacturers for their microbiome-related development and production needs. Outsourcing is known to offer several benefits, which include reductions in capital investment, access to larger production capacities, expediting time-to-market, and commercial risk handling and mitigation (to a significant extent). Presently, a number of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) claim to offer services for manufacturing microbiome-related products. In fact, some have even developed end-to-end capabilities, starting from drug development to regulatory filings, and commercial scale production, in this field.

Scope of the Report

The “Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030” report features an extensive study of the current landscape and future opportunities related to contract services for microbiome therapeutics. The study features an in-depth analysis, highlighting the capabilities of a diverse set of contract service providers, including CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company’s contact details. 
  • A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise). 
  • Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook.
  • An assessment of microbiome contract manufacturing capability in different regions, based on a number of relevant parameters, such as number of CMOs, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of companies offering API / FDF manufacturing, number of companies having capabilities for preclinical / clinical / commercial manufacturing, number of companies dedicated to aerobic / anaerobic fermentation, installed manufacturing capacity, and number of in-house players.
  • A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account the company’s size and its experience in this field), company’s pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.
  • A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.
  • An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).
  • An informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity,  and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters. 

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbiome therapeutics contract manufacturing market. Based on multiple parameters, such as projected growth of the overall microbiome therapeutics market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of  product manufactured (API and FDF), [B] type of formulation (solids, oral liquids, injectables and others), [C] company size (small-sized, mid-sized and large), [D] scale of operation (clinical and commercial), and [E] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study was influenced by inputs solicited via a survey and discussions held with multiple senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following individuals:

  • Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic) 
  • Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals) 
  • Assaf Oron (Chief Business Officer, BiomX)
  • Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies) 
  • Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories) 
  • JP Benya (Vice President, Business Development, Assembly Biosciences) 
  • Rob van Dijk (Business Development Manager, Wacker Biotech) 
  • Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical) 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading CMOs offering microbiome contract manufacturing services, across the world?
  • What are the key challenges faced by microbiome contract manufacturers?
  • Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?
  • What is the annual clinical demand for microbiome-based live biotherapeutic products? 
  • What is the current, installed contract manufacturing capacity for live biotherapeutics?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?
  • What are the various initiatives undertaken by big pharma players in this domain? 
  • What percentage of live biotherapeutics manufacturing operations are outsourced to service providers?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to live biotherapeutics manufacturing?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics contract manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the Human Microbiome Project (HMP). Further, the chapter also includes a description of the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.

Chapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 25 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company’s contact details. A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise). 

Chapter 5 includes detailed profiles of key industry players (large and mid-sized companies established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook

Chapter 6 features an informed assessment of microbiome contract manufacturing capability in different regions, based on a number of relevant parameters, such as number of CMOs, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of companies offering API / FDF manufacturing, number of companies having capabilities for preclinical / clinical / / commercial manufacturing, number of companies dedicated to aerobic / anaerobic fermentation, installed manufacturing capacity, and number of in-house players.

Chapter 7 features a list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company’s size and its experience in this field), company’s pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.

Chapter 8 provides a detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.

Chapter 9 features an estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).

Chapter 10 features an informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.

Chapter 11 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 12 a review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity,  and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

Chapter 13 features an elaborate market forecast analysis, highlighting the likely growth of microbiome contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of  product manufactured (API and FDF), B] type of formulation (solids, oral liquids, injectables and others), [C] company size ( small-sized, mid-sized and large), [D] scale of operation (clinical and commercial), and [E] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Gaurav Kaushik (Managing Director and Chief Executive Officer, Meteoric Biopharmaceuticals), Assaf Oron (Chief Business Officer, BiomX), Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), JP Benya (Vice President, Business Development, Assembly Biosciences), Rob van Dijk (Business Development Manager, Wacker Biotech), and Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Chapter 18 is an appendix, which contains the list of companies that claim to offer contract manufacturing for probiotic supplements and microbial strains.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Human Microbiota and Microbiome
3.3. Overview of Gut Flora
3.2.3. Role of Gut Flora in Healthy Individuals
3.2.4. Factors Affecting Human Gut Flora

3.4. The Human Microbiome Project (HMP)
3.5. Overview of Microbiome Therapies
3.5.1. Types of Microbiome Therapies
3.5.1.1. Probiotics
3.5.1.2. Prebiotics

3.5.2. Applications of Microbiome Therapies
3.5.3. Microbiome Therapies Supply Chain

3.6. Microbiome-based Product Manufacturing
3.6.1. Key Steps Involved
3.6.2. Associated Challenges
3.6.3. Role of Contract Manufacturing Organizations (CMOs)
3.6.4. Demand for Contract Manufacturing Services

3.7. Key Considerations for Selecting a Suitable CMO Partner

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CMOs Offering Contract Manufacturing for Microbiome Therapeutics: List of Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size 
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Type of Product Manufactured
4.2.7. Analysis by Type of Drug Molecule
4.2.8. Analysis by Type of Fermentation Required
4.2.9. Analysis by Type of Formulation
4.2.10. Analysis by Type of Primary Packaging Used
4.2.11. Analysis by Number of Manufacturing Facilities
4.2.12. Analysis by Location of Manufacturing Facilities
4.2.13. Analysis by Type of Regulatory Certifications / Accreditations

4.3. Microbiome Therapeutics In-House Manufacturers: List of Companies
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Scale of Operation
4.3.4. Analysis by Location of Headquarters
4.3.5. Analysis by Location of Manufacturing Facilities

5. COMPANY PROFILES
5.1. Chapter Overview

5.2. CMOs Headquartered in North America
5.2.1. Capsugel
5.2.1.1. Company Overview
5.2.1.2. Microbiome-Related Service Portfolio
5.2.1.3. Facilities Dedicated to Microbiome Manufacturing
5.2.1.4. Recent Developments and Future Outlook

5.2.2. Paragon Bioservices
5.2.2.1. Company Overview
5.2.2.2. Microbiome-Related Service Portfolio
5.2.2.3. Facilities Dedicated to Microbiome Manufacturing
5.2.2.4. Recent Developments and Future Outlook

5.2.3. UAS Labs
5.2.3.1. Company Overview
5.2.3.2. Microbiome-Related Service Portfolio
5.2.3.3. Facilities Dedicated to Microbiome Manufacturing
5.2.3.4. Recent Developments and Future Outlook

5.3. CMOs Headquartered in Europe
5.3.1. Biose
5.3.1.1. Company Overview
5.3.1.2. Microbiome-Related Service Portfolio
5.3.1.3. Facilities Dedicated to Microbiome Manufacturing
5.3.1.4. Recent Developments and Future Outlook

5.3.2. Cobra Biologics
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Microbiome-Related Service Portfolio
5.3.2.4. Facilities Dedicated to Microbiome Manufacturing
5.3.2.5. Recent Developments and Future Outlook

5.3.3. Cerbios
5.3.3.1. Company Overview
5.3.3.2. Microbiome-Related Service Portfolio
5.3.3.3. Facilities Dedicated to Microbiome Manufacturing
5.3.3.4. Recent Developments and Future Outlook

5.3.4. Inpac Probiotics
5.3.4.1. Company Overview
5.3.4.2. Microbiome-Related Service Portfolio
5.3.4.3. Facilities Dedicated to Microbiome Manufacturing
5.4. CMOs Headquartered in Asia-Pacific and Rest of the World
5.4.1. BJP Laboratories
5.4.1.1. Company Overview
5.4.1.2. Microbiome-Related Service Portfolio
5.4.1.3. Facilities Dedicated to Microbiome Manufacturing

6. REGIONAL CAPABILITY ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Regional Capability Analysis: Microbiome Contract Manufacturers in North America
6.4. Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
6.5. Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
6.6. Concluding Remarks

7. LIKELY PARTNER ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Microbiome Contract Manufacturers
7.3.1. Opportunities in North America
7.3.2. Opportunities in Europe and Asia-Pacific

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Clinical Trial Analysis (Industry Players)
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Phase
8.3.3. Analysis by Trial Recruitment Status
8.3.4. Analysis by Trial Registration Year and Recruitment Status
8.3.5. Analysis by Trial Registration Year and Number of Patients Enrolled
8.3.6. Analysis by Study Design
8.3.7. Analysis by Trial Focus
8.3.8. Analysis by Trial Phase and Type of Intervention Model
8.3.9. Analysis by Sponsor / Collaborator
8.3.10. Analysis by Type of Organization
8.3.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year 
8.3.12. Geographical Analysis by Number of Clinical Trials
8.3.13. Geographical Analysis by Trial Recruitment Status

8.4. Clinical Trial Analysis (Non-Industry Players)
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Phase
8.4.3. Analysis by Trial Recruitment Status
8.4.4. Analysis by Trial Registration Year and Recruitment Status
8.4.5. Analysis by Trial Registration Year and Number of Patients Enrolled
8.4.6. Analysis by Study Design
8.4.7. Analysis by Trial Focus
8.4.8. Analysis by Trial Phase and Type of Intervention Model
8.4.9. Analysis by Sponsor / Collaborator
8.4.10. Analysis by Type of Organization
8.4.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year 
8.4.12. Geographical Analysis by Number of Clinical Trials
8.4.13. Geographical Analysis by Trial Recruitment Status

9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology

9.3. Microbiome Contract Manufacturers: Global Production Capacity 
9.3.1. Analysis by Company Size
9.3.1.1. Overall Production Capacity of Small-sized Companies
9.3.1.2. Overall Production Capacity of Mid-sized Companies
9.3.1.3. Overall Production Capacity of Large Companies

9.3.2. Analysis by Scale of Operation
9.3.2.1. Overall Clinical Scale Production Capacity
9.3.2.2. Overall Commercial Scale Production Capacity

9.3.3. Analysis by Location of Manufacturing Facility
9.3.3.1. Overall Production Capacity in North America
9.3.3.2. Overall Production Capacity in Europe
9.3.3.3. Overall Production Capacity in Asia-Pacific and Rest of the World

9.4. Concluding Remarks

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Global Clinical Demand for Microbiome Contract Manufacturing

10.3.1. Geographical Analysis of Demand
10.3.1.1. Clinical Demand in North America
10.3.1.2. Clinical Demand in Europe
10.3.1.3. Clinical Demand in Asia-Pacific and Rest of the World

10.3.2. Phase-Wise Analysis of Demand
10.3.2.1. Clinical Demand in Phase I
10.3.2.2. Clinical Demand in Phase II
10.3.2.3. Clinical Demand in Phase III

10.3.3. Sponsor Wise Analysis of Demand
10.3.2.1. Clinical Demand for Industry Sponsors
10.3.2.2. Clinical Demand for Non-Industry Sponsors

10.4 Concluding Remarks

11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
11.1. Chapter Overview
11.2. Make versus Buy Decision Making: Assumptions and Parameter Definitions
11.2.1. Scenario 1: High Value Addition / Low Complexity
11.2.1. Scenario 2: High Value Addition / High Complexity
11.2.1. Scenario 3: Low Value Addition / Low Complexity
11.2.1. Scenario 4: Low Value Addition / High Complexity
11.3. Contract Manufacturer’s Perspective
11.4. Concluding Remarks

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
12.1. Chapter Overview
12.2. Scope and Methodology

12.3. Initiatives of Big Pharmaceutical Players
12.3.1. Analysis by Portfolio Diversity
12.3.2. Analysis by Phase of Development
12.3.3. Analysis by Type of Therapeutic
12.3.4. Analysis by Type of Drug Molecule
12.3.5. Heat Map: Analysis by Target Therapeutic Areas

12.4. Benchmark Analysis of Big Pharmaceutical Players
12.4.1. Spider Web Analysis: Company A
12.4.2. Spider Web Analysis: Company B
12.4.3. Spider Web Analysis: Company C
12.4.4. Spider Web Analysis: Company D
12.4.5. Spider Web Analysis: Company E
12.4.6. Spider Web Analysis: Company F
12.4.7. Spider Web Analysis: Company G
12.4.8. Spider Web Analysis: Company H
12.4.9. Spider Web Analysis: Company I
12.4.10. Spider Web Analysis: Company J
12.4.11. Spider Web Analysis: Company K

12.5. Concluding Remarks

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Microbiome Contract Manufacturing Market, 2020-2030

13.4 Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Product Manufactured
13.4.1. Microbiome Contract Manufacturing Market for APIs, 2020-2030
13.4.2. Microbiome Contract Manufacturing Market for FDFs, 2020-2030

13.5. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Type of Formulation
13.5.1. Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030
13.5.2. Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030
13.5.3. Microbiome Contract Manufacturing Market for Injectables, 2020-2030
13.5.4. Microbiome Contract Manufacturing Market for Others, 2020-2030

13.6. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.6.1. Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030
13.6.2. Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030

13.7. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Company Size
13.7.1. Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030
13.7.2. Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030
13.7.3. Microbiome Contract Manufacturing Market for Large Companies, 2020-2030

13.8. Microbiome Contract Manufacturing Market, 2020-2030: Geographical Distribution
13.8.1. Microbiome Contract Manufacturing Market in North America, 2020-2030
13.8.2. Microbiome Contract Manufacturing Market in Europe, 2020-2030
13.8.3. Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030
13.9. Concluding Remarks

14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. S-Biomedic
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer

15.3. Meteoric Biopharmaceuticals
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer

15.4. BiomX
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Assaf Oron, Chief Business Officer

15.5. Universal Stabilization Technologies
15.5.1 Company Snapshot
15.5.2. Interview Transcript: Alexander Segal, Vice President, Business Development
15.6. List Biological Laboratories
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development

15.7. Assembly Biosciences
15.7.1. Company Snapshot
15.7.2. Interview Transcript: JP Benya, Vice President, Business Development

15.8. Wacker Biotech
15.8.1 Company Snapshot
15.8.2. Interview Transcript: Rob van Dijk, Business Development Manager

15.9. Chung Mei Pharmaceutical
15.9.1. Company Snapshot
15.9.2. Interview Transcript: Alexander Lin, Associate General Manager

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

18. APPENDIX III: LIST OF PROBIOTIC SUPPLEMENT CONTRACT MANUFACTURERS AND MICROBIAL CONTACT SERVICE PROVIDERS

List Of Figures

Figure 3.1 Benefits of the Human Microbiota
Figure 3.2 Factors Affecting Gut Flora
Figure 3.3 Human Microbiome Project: Key Achievements
Figure 3.4 Microbiome Therapies: Design Approaches
Figure 3.5 Types of Microbiome Therapies
Figure 3.6 Probiotic Drugs: Overview of Beneficial Bacterial Strains
Figure 3.7 Microbiome Therapies: Potential Application Areas
Figure 3.8 Key Steps Involved in Microbiome Therapeutics Supply Chain 
Figure 3.9 Key Steps Involved in Microbiome Therapeutics Manufacturing 
Figure 3.10 Key Challenges in Manufacturing of Microbiome Therapeutics
Figure 3.11 Key Strategies to Increase Efficiency of Manufacturing Microbiome Therapeutics
Figure 3.12 Microbiome Manufacturing Industry Survey (December 2018): Distribution by Respondent Particulars
Figure 3.13 Microbiome Manufacturing Industry Survey (December 2018): Distribution by Manufacturing Preference
Figure 4.1 Microbiome Therapeutics Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Microbiome Therapeutics Contract Manufacturers: Distribution by Company Size
Figure 4.3 Microbiome Therapeutics Contract Manufacturers: Distribution by Scale of Operation
Figure 4.4 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Headquarters
Figure 4.5 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Service Offered
Figure 4.6 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Product Manufactured
Figure 4.7 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Drug Molecule
Figure 4.8 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Fermentation Required
Figure 4.9 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Formulation
Figure 4.10 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Primary Packaging Used
Figure 4.11 Microbiome Therapeutics Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Figure 4.12 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.13 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Regulatory Certifications / Accreditations
Figure 4.14 Microbiome Therapeutics In-House Manufacturers: Distribution by Year of Establishment
Figure 4.15 Microbiome Therapeutics In-House Manufacturers: Distribution by Company Size
Figure 4.16 Microbiome Therapeutics In-House Manufacturers: Distribution by Scale of Operation
Figure 4.17 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Headquarters
Figure 4.18 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 5.1 Capsugel: Microbiome-Related Service Portfolio
Figure 5.2 Paragon Bioservices: Microbiome-Related Service Portfolio
Figure 5.3 UAS Labs: Microbiome-Related Service Portfolio
Figure 5.4 Biose: Microbiome-Related Service Portfolio
Figure 5.5 Cerbios: Microbiome-Related Service Portfolio
Figure 5.6 Cobra Biologics: Microbiome-Related Service Portfolio
Figure 5.7 Inpac Probiotics: Microbiome-Related Service Portfolio
Figure 5.8 BJP Laboratories: Microbiome-Related Service Portfolio
Figure 6.1 Regional Capability Analysis: Microbiome Contract Manufacturers in North America
Figure 6.2 Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
Figure 6.3 Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
Figure 6.4 Regional Capability Analysis: Comparison of Capabilities across Different Regions
Figure 8.1 Clinical Trial Analysis: Scope and Methodology
Figure 8.2 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year
Figure 8.3 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis for Industry Players: Distribution by Trial Recruitment Status
Figure 8.5 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Recruitment Status
Figure 8.6 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 8.7 Clinical Trial Analysis for Industry Players: Distribution by Study Design
Figure 8.8 Clinical Trial Analysis for Industry Players: Distribution by Trial Focus
Figure 8.9 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase and Type of Intervention Model
Figure 8.10 Clinical Trial Analysis for Industry Players: Distribution by Sponsor / Collaborator
Figure 8.11 Clinical Trial Analysis for Industry Players: Distribution by Type of Organization
Figure 8.12 Clinical Trial Analysis for Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
Figure 8.13 Clinical Trial Analysis for Industry Players: Geographical Distribution by Number of Clinical Trials
Figure 8.14 Clinical Trial Analysis for Industry Players: Geographical Distribution by Trial Recruitment Status
Figure 8.15 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year
Figure 8.16 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase
Figure 8.17 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Recruitment Status
Figure 8.18 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Recruitment Status
Figure 8.19 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 8.20 Clinical Trial Analysis for Non-Industry Players: Distribution by Study Design
Figure 8.21 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Focus
Figure 8.22 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase and Type of Intervention Model
Figure 8.23 Clinical Trial Analysis for Non-Industry Players: Distribution by Sponsor / Collaborator
Figure 8.24 Clinical Trial Analysis for Non-Industry Players: Distribution by Type of Organization
Figure 8.25 Clinical Trial Analysis for Non-Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
Figure 8.26 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Number of Clinical Trials
Figure 8.27 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Trial Recruitment Status
Figure 9.1 Microbiome Contract Manufacturing Capacity: Distribution by Company Size
Figure 9.2 Microbiome Contract Manufacturing Capacity of Small-sized Companies (Kilo Liters)
Figure 9.3 Microbiome Contract Manufacturing Capacity of Mid-sized Companies (Kilo Liters)
Figure 9.4 Microbiome Contract Manufacturing Capacity of Large Companies (Kilo Liters)
Figure 9.5 Microbiome Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 9.6 Clinical Scale Microbiome Contract Manufacturing Capacity (Kilo Liters)
Figure 9.7 Commercial Scale Microbiome Contract Manufacturing Capacity (Kilo Liters)
Figure 9.8 Microbiome Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 9.9 Microbiome Contract Manufacturing Capacity in North America (Kilo Liters)
Figure 9.10 Microbiome Contract Manufacturing Capacity in Europe (Kilo Liters)
Figure 9.11 Microbiome Contract Manufacturing Capacity in Asia-Pacific and Rest of the World (Kilo Liters)
Figure 10.1 Current Clinical Demand for Microbiome Contract Manufacturing: Scope and Methodology
Figure 10.2 Microbiome-based Live Biotherapeutics Pipeline: Distribution by Phase of Development
Figure 10.3 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Trials Conducted)
Figure 10.4 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Enrolled Patients)
Figure 10.5 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Geography, 2025 and 2030 (Number of Enrolled Patients)
Figure 10.6 Current Clinical Demand for Microbiome Contract Manufacturing in North America, 2019 (Number of Enrolled Patients)
Figure 10.7 Clinical Demand for Microbiome Contract Manufacturing in North America, 2020-2030 (Number of Enrolled Patients)
Figure 10.8 Current Clinical Demand for Microbiome Contract Manufacturing in Europe, 2019 (Number of Enrolled Patients)
Figure 10.9 Clinical Demand for Microbiome Contract Manufacturing in Europe, 2020-2030 (Number of Enrolled Patients)
Figure 10.10 Current Clinical Demand for Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2019 (Number of Enrolled Patients)
Figure 10.11 Clinical Demand for Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2020-2030 (Number of Enrolled Patients)
Figure 10.12 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Phase of Development, 2025 and 2030 (Number of Enrolled Patients)
Figure 10.13 Clinical Demand for Microbiome Contract Manufacturing in Phase I Trials, 2020-2030 (Number of Enrolled Patients)
Figure 10.14 Clinical Demand for Microbiome Contract Manufacturing in Phase II Trials, 2020-2030 (Number of Enrolled Patients)
Figure 10.15 Clinical Demand for Microbiome Contract Manufacturing in Phase III Trials, 2020-2030 (Number of Enrolled Patients)
Figure 10.16 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Type of Sponsor, 2025 and 2030 (Number of Enrolled Patients)
Figure 10.17 Clinical Demand for Microbiome Contract Manufacturing in Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
Figure 10.18 Clinical Demand for Microbiome Contract Manufacturing in Non-Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
Figure 11.1 Make versus Buy Decision Making Framework
Figure 11.2 Make versus Buy Decision Making: Description of Possible Scenarios
Figure 11.3 Make versus Buy Thinking: Contract Manufacturers’ Perspective
Figure 12.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 12.2 Big Pharma Players: Analysis by Portfolio Diversity
Figure 12.3 Big Pharma Players: Analysis by Phase of Development
Figure 12.4 Big Pharma Players: Analysis by Type of Therapeutic
Figure 12.5 Big Pharma Players: Analysis by Type of Drug Molecule
Figure 12.6 Big Pharma Players: Analysis by Target Therapeutic Areas
Figure 12.7 Spider Web Analysis: Company A
Figure 12.8 Spider Web Analysis: Company B
Figure 12.9 Spider Web Analysis: Company C
Figure 12.10 Spider Web Analysis: Company D
Figure 12.11 Spider Web Analysis: Company E
Figure 12.12 Spider Web Analysis: Company F
Figure 12.13 Spider Web Analysis: Company G
Figure 12.14 Spider Web Analysis: Company H
Figure 12.15 Spider Web Analysis: Company I
Figure 12.16 Spider Web Analysis: Company J
Figure 12.17 Spider Web Analysis: Company K
Figure 13.1 Commercial Microbiome Contract Manufacturing: Market Forecast Methodology
Figure 13.2 Clinical Trial Analysis for Industry Players: Distribution by Type of Sponsor, 2019 (Number of Enrolled Patients)
Figure 13.3 Clinical Microbiome Contract Manufacturing: Market Forecast Methodology
Figure 13.4 Overall Microbiome Contract Manufacturing Market, 2020-2030 (USD Million)
Figure 13.5 Microbiome Contract Manufacturing Market, 2020 and 2030: Distribution by Product Manufactured (USD Million)
Figure 13.6 Microbiome Contract Manufacturing Market for APIs, 2020-2030 (USD Million)
Figure 13.7 Microbiome Contract Manufacturing Market for FDFs, 2020-2030 (USD Million)
Figure 13.8 Microbiome Contract Manufacturing Market: Distribution by Type of Formulation, 2020 and 2030 (USD Million)
Figure 13.9 Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030 (USD Million)
Figure 13.10 Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030 (USD Million)
Figure 13.11 Microbiome Contract Manufacturing Market for Injectables, 2020-2030 (USD Million)
Figure 13.12 Microbiome Contract Manufacturing Market for Others, 2020-2030 (USD Million)
Figure 13.13 Microbiome Contract Manufacturing Market: Distribution by Scale of Operation, 2020 and 2030 (USD Million)
Figure 13.14 Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030 (USD Million)
Figure 13.15 Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Million)
Figure 13.16 Microbiome Contract Manufacturing Market: Distribution by Company Size, 2020 and 2030 (USD Million)
Figure 13.17 Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030 (USD Million)
Figure 13.18 Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Million)
Figure 13.19 Microbiome Contract Manufacturing Market for Large Companies, 2020-2030 (USD Million)
Figure 13.20 Microbiome Contract Manufacturing Market: Distribution by Geography, 2020 and 2030 (USD Million)
Figure 13.21 Microbiome Contract Manufacturing Market in North America, 2020-2030 (USD Million)
Figure 13.22 Microbiome Contract Manufacturing Market in Europe, 2020-2030 (USD Million)
Figure 13.23 Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
Figure 13.24 Microbiome Contract Manufacturing Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)

List Of Tables

Table 3.1 Different Types of Microbiota in the Gastrointestinal Tract
Table 3.2 Foods Containing Prebiotics
Table 3.3 Comparison of Key Factors for the Selection of CMOs: Harvey Ball Analysis
Table 4.1 Microbiome Therapeutics Contract Manufacturers: List of Companies
Table 4.2 Microbiome Therapeutics Contract Manufacturers: Information on Type of Service Offered
Table 4.3 Microbiome Therapeutics Contract Manufacturers: Information on Type of Product Manufactured
Table 4.4 Microbiome Therapeutics Contract Manufacturers: Information on Type of Drug Molecule
Table 4.5 Microbiome Therapeutics Contract Manufacturers: Information on Type of Fermentation Required
Table 4.6 Microbiome Therapeutics Contract Manufacturers: Information on Type of Formulation
Table 4.7 Microbiome Therapeutics Contract Manufacturers: Information on Type of Primary Packaging Used
Table 4.8 Microbiome Therapeutics Contract Manufacturers: Information on Manufacturing Facilities
Table 4.9 Microbiome Therapeutics Contract Manufacturers: Information on Type of Regulatory Certifications / Accreditations
Table 4.10 Microbiome Therapeutics Contract Manufacturers: Information on Contact Details
Table 4.11 Microbiome Therapeutics In-House Manufacturers: List of Companies
Table 4.12 Microbiome Therapeutics In-House Manufacturers: Information on Manufacturing Facilities
Table 5.1 Microbiome Contract Manufacturing Organizations: List of Companies Profiled
Table 5.2 Capsugel: Recent Developments and Future Outlook
Table 5.3 Paragon Bioservices: Recent Developments and Future Outlook
Table 5.4 UAS Labs: Recent Developments and Future Outlook
Table 5.5 Biose: Recent Developments and Future Outlook
Table 5.6 Cobra Biologics: Recent Developments and Future Outlook
Table 5.7 Cerbios: Recent Developments and Future Outlook
Table 7.1 Likely Partners in North America
Table 7.2 Likely Partners in Europe and Asia-Pacific
Table 9.1 Microbiome Therapeutics Contract Manufacturers: Average Capacity by Company Size (Sample Data Set)
Table 9.2 Microbiome Therapeutics Contract Manufacturers: Total Installed Capacity by Company Size
Table 10.1 Clinical Demand for Microbiome Contract Manufacturing: Phase wise Distribution of Average Number of Enrolled Patients
Table 12.1 Big Pharma Players: Spider-Web Analysis (Input Data)
Table 14.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Summary of the Competitive Insights
Table 15.1 S-Biomedic: Company Snapshot
Table 15.2 Meteoric Biopharmaceuticals: Company Snapshot
Table 15.3 BiomX: Company Snapshot
Table 15.4 Universal Stabilization Technologies: Company Snapshot
Table 15.5 List Biological Laboratories: Company Snapshot
Table 15.6 Assembly Biosciences: Company Snapshot
Table 15.7 Wacker Biotech: Company Snapshot
Table 15.8 Chung Mei Pharmaceutical: Company Snapshot
Table 16.1 Survey Respondents (December 2018): Distribution by Respondent Particulars
Table 16.2 Survey Respondents (December 2018): Distribution by Manufacturing Preference
Table 16.3 Microbiome Therapeutics Contract Manufacturers: Distribution by Year of Establishment
Table 16.4 Microbiome Therapeutics Contract Manufacturers: Distribution by Company Size
Table 16.5 Microbiome Therapeutics Contract Manufacturers: Distribution by Scale of Operation
Table 16.6 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Headquarters
Table 16.7 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Service Offered
Table 16.8 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Product Manufactured
Table 16.9 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Drug Molecule
Table 16.10 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Fermentation Required
Table 16.11 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Formulation
Table 16.12 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Primary Packaging Used
Table 16.13 Microbiome Therapeutics Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Table 16.14 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 16.15 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Regulatory Certifications / Accreditations
Table 16.16 Microbiome Therapeutics In-House Manufacturers: Distribution by Year of Establishment
Table 16.17 Microbiome Therapeutics In-House Manufacturers: Distribution by Company Size
Table 16.18 Microbiome Therapeutics In-House Manufacturers: Distribution by Scale of Operation
Table 16.19 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Headquarters
Table 16.20 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Manugacturing Facilities
Table 16.21 Regional Capability Analysis: Microbiome Contract Manufacturers in North America
Table 16.22 Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
Table 16.23 Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
Table 16.24 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year
Table 16.25 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase
Table 16.26 Clinical Trial Analysis for Industry Players: Distribution by Trial Recruitment Status
Table 16.27 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Recruitment Status
Table 16.28 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 16.29 Clinical Trial Analysis for Industry Players: Distribution by Study Design
Table 16.30 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase and Type of Intervention Model
Table 16.31 Clinical Trial Analysis for Industry Players: Distribution by Sponsor / Collaborator
Table 16.32 Clinical Trial Analysis for Industry Players: Distribution by Type of Organization
Table 16.33 Clinical Trial Analysis for Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
Table 16.34 Clinical Trial Analysis for Industry Players: Geographical Distribution by Number of Clinical Trials
Table 16.35 Clinical Trial Analysis for Industry Players: Geographical Distribution by Trial Recruitment Status
Table 16.36 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year
Table 16.37 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase
Table 16.38 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Recruitment Status
Table 16.39 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Recruitment Status
Table 16.40 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 16.41 Clinical Trial Analysis for Non-Industry Players: Distribution by Study Design
Table 16.42 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase and Type of Intervention Model
Table 16.43 Clinical Trial Analysis for Non-Industry Players: Distribution by Sponsor / Collaborator
Table 16.44 Clinical Trial Analysis for Non-Industry Players: Distribution by Type of Organization
Table 16.45 Clinical Trial Analysis for Non-Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
Table 16.46 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Number of Clinical Trials
Table 16.47 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Trial Recruitment Status
Table 16.48 Microbiome Contract Manufacturing Capacity: Distribution by Company Size
Table 16.49 Microbiome Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 16.50 Microbiome Contract Manufacturing Capacity: Distribution by Geography
Table 16.51 Microbiome Contract Manufacturing Capacity in North America (Kilo Liters)
Table 16.52 Microbiome Contract Manufacturing Capacity in Europe (Kilo Liters)
Table 16.53 Microbiome Contract Manufacturing Capacity in Asia-Pacific and Rest of the World (Kilo Liters)
Table 16.54 Microbiome-based Live Biotherapeutics Pipeline: Distribution by Phase of Development
Table 16.55 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Trials Conducted)
Table 16.56 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Enrolled Patients)
Table 16.57 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Geography, 2025 and 2030 (Number of Enrolled Patients)
Table 16.58 Clinical Demand for Microbiome Contract Manufacturing in North America, 2020-2030 (Number of Enrolled Patients)
Table 16.59 Current Clinical Demand for Microbiome Contract Manufacturing in Europe, 2020-2030 (Number of Enrolled Patients)
Table 16.60 Current Clinical Demand for Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2020-2030 (Number of Enrolled Patients)
Table 16.61 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Phase of Development, 2025 and 2030 (Number of Enrolled Patients)
Table 16.62 Clinical Demand for Microbiome Contract Manufacturing in Phase I Trials, 2020-2030 (Number of Enrolled Patients)
Table 16.63 Clinical Demand for Microbiome Contract Manufacturing in Phase II Trials, 2020-2030 (Number of Enrolled Patients)
Table 16.64 Clinical Demand for Microbiome Contract Manufacturing in Phase III Trials, 2020-2030 (Number of Enrolled Patients)
Table 16.65 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Type of Sponsor, 2025 and 2030 (Number of Enrolled Patients)
Table 16.66 Clinical Demand for Microbiome Contract Manufacturing in Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
Table 16.67 Clinical Demand for Microbiome Contract Manufacturing in Non-Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
Table 16.68 Clinical Trial Analysis for Industry Players: Distribution by Type of Sponsor, 2019 (Number of Enrolled Patients)
Table 16.69 Overall Microbiome Contract Manufacturing Market, 2020-2030 (USD Million)
Table 16.70 Microbiome Contract Manufacturing Market: Distribution by Product Manufactured, 2020 and 2030 (USD Million)
Table 16.71 Microbiome Contract Manufacturing Market for APIs, 2020-2030 (USD Million)
Table 16.72 Microbiome Contract Manufacturing Market for FDFs, 2020-2030 (USD Million)
Table 16.73 Microbiome Contract Manufacturing Market: Distribution by Type of Formulation, 2020 and 2030 (USD Million)
Table 16.74 Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030 (USD Million)
Table 16.75 Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030 (USD Million)
Table 16.76 Microbiome Contract Manufacturing Market for Injectables, 2020-2030 (USD Million)
Table 16.77 Microbiome Contract Manufacturing Market for Others, 2020-2030 (USD Million)
Table 16.78 Microbiome Contract Manufacturing Market: Distribution by Scale of Operation, 2020 and 2030 (USD Million)
Table 16.79 Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030 (USD Million)
Table 16.80 Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Million)
Table 16.81 Microbiome Contract Manufacturing Market: Distribution by Company Size, 2020 and 2030 (USD Million)
Table 16.82 Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030 (USD Million)
Table 16.83 Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Million)
Table 16.84 Microbiome Contract Manufacturing Market for Large Companies, 2020-2030 (USD Million)
Table 16.85 Microbiome Contract Manufacturing Market: Distribution by Geography, 2020 and 2030 (USD Million)
Table 16.86 Microbiome Contract Manufacturing Market in North America, 2020-2030 (USD Million)
Table 16.87 Microbiome Contract Manufacturing Market in Europe, 2020-2030 (USD Million)
Table 16.88 Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
Table 16.89 Microbiome Contract Manufacturing Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Table 18.1 Probiotic Supplement Contract Manufacturers: List of Companies
Table 18.2 Microbial Contract Manufacturers: List of Companies

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. 3SBio
  3. 4D Pharma
  4. 53Biologics
  5. AbbVie
  6. AbbVie Contract Manufacturing
  7. ABCO Laboratories
  8. ABH Pharma
  9. AceBiome
  10. ActoBio Therapeutics (a subsidiary of Intrexon)
  11. Actygea
  12. Adare Pharmaceuticals
  13. ADM Biopolis
  14. ADM Protexin
  15. Advanced BioScience Laboratories
  16. Advanced Enzymes
  17. Affinity Life Sciences
  18. AGC Biologics
  19. Ajinomoto Bio-Pharma Services
  20. Albumedix
  21. Aldevron
  22. Allergan
  23. Allianz Biosciences
  24. AMAbiotics
  25. AMRI
  26. AOBiome Therapeutics
  27. APC Microbiome Institute
  28. Armata Pharmaceuticals
  29. Arranta Bio
  30. Assembly Biosciences
  31. AST Enzymes
  32. AstraZeneca
  33. Atlantic Essential Products
  34. Aumgene Biosciences
  35. AURA Biotechnologies
  36. Axcellerate Pharma
  37. Axial Biotherapeutics
  38. Azitra
  39. BacThera
  40. Batavia Biosciences
  41. Baylor College of Medicine
  42. Biena
  43. Bifodan
  44. Binex
  45. Bio Elpida
  46. Bio Farma
  47. Bio Synergy
  48. BioCare Copenhagen
  49. BioCell
  50. Biocodex
  51. BIOFABRI
  52. BioGaia
  53. Bio-K Plus International
  54. Biological E.
  55. BioMARC
  56. Biomica (a subsidiary of Evogene)
  57. BiomX
  58. BioProduction by Sekisui
  59. biose
  60. Biosortia Pharmaceuticals
  61. Bio-Synthesis
  62. Bio-Technology General
  63. BioThrive Sciences
  64. BioVectra
  65. Biovian
  66. BJP Laboratories
  67. Bloom Science
  68. Blue Turtle Bio Technologies
  69. Boehringer Ingelheim BioXcellence
  70. Boston Analytical
  71. Boston Institute of Biotechnology
  72. Boston Medical Center
  73. Bristol-Myers Squibb
  74. Broad Institute
  75. Caelus Health
  76. Capsugel
  77. Capua BioServices
  78. Carbiotix
  79. Catalent Biologics
  80. Cell Biotech
  81. Cerbios-Pharma
  82. CEVEC Pharmaceuticals
  83. CHAIN Biotechnology
  84. Charles River Laboratories
  85. ChemPartner Biologics
  86. CinnaGen
  87. ClostraBio
  88. Cobra Biologics
  89. Commense (a subsidiary of PureTech Health)
  90. Concord Biotech
  91. Corden BioChem
  92. Creative Biolabs
  93. Crown Laboratories
  94. Custom Probiotics
  95. Cytovance Biologics
  96. DANIN International
  97. DaVolterra
  98. DayTwo
  99. Deerland Probiotics & Enzymes
  100. DermBiont
  101. DuPont
  102. EirGenix
  103. EKF Life Sciences
  104. Elmed
  105. Emerge Nutraceuticals
  106. Emergent Biosolutions
  107. EMF
  108. Enteris BioPharma
  109. Enterome
  110. Etinpro
  111. EuBiologics
  112. EUCODIS Bioscience
  113. Eurogentec
  114. Evelo Biosciences
  115. Evogene
  116. Evonik Health Care
  117. EXDEN
  118. Exeliom Biosciences
  119. Exim Pharma
  120. Ferring Pharmaceuticals
  121. Finch Therapeutics
  122. Food and Agriculture Organization
  123. FUJIFILM Diosynth Biotechnologies
  124. Ganeden
  125. GE Healthcare
  126. GenIbet Biopharmaceuticals
  127. GENIBIO (a subsidiary of the LARENA and GB ACTION)
  128. Genome and Company
  129. GI Innovation
  130. GSK Contract Manufacturing
  131. GTP Technology
  132. Gusto Global
  133. Holobiome
  134. Hong Kong Institute of Biotechnology
  135. Igen Biotech
  136. ImmuneBiotech
  137. Immuron
  138. Infact Bacterial Therapeutics
  139. Inpac Probiotics
  140. Institute for Research in Biomedicine (IRB)
  141. Intron Life Sciences (ILS)
  142. Ion Labs
  143. IVERIC bio
  144. J. Craig Venter Institute
  145. Jeneil Biotech
  146. JLABS
  147. Johnson & Johnson
  148. JW Nutritional
  149. Kaleido Biosciences
  150. Kallyope
  151. Kanda Biotech
  152. Karyotica Biologicals
  153. KBI Biopharma
  154. Kendy Pharma
  155. Kibow Biotech
  156. KNect365 Life Sciences
  157. LakePharma
  158. Lallemand
  159. Leadiant Biosciences
  160. List Biological Laboratories
  161. LNC Therapeutics
  162. Locus Biosciences
  163. Lonza
  164. LUCA Biologics
  165. Luina Bio
  166. Mabion Poland
  167. Maine Biotechnology Services
  168. MatriSys Bioscience
  169. Medella Naturals
  170. Medella Springs Healthcare
  171. Menarini Biotech
  172. Merck
  173. Merck Millipore
  174. MeriCal
  175. Meridian Life Science
  176. MetaboGen
  177. Meteoric Biopharmaceuticals
  178. Microbax
  179. MicroBiopharm Japan
  180. Microbiotica
  181. Mologic
  182. MyBiotics
  183. Mycenax Biotech
  184. Naked Biome
  185. National Cancer Institute (NCI)
  186. National Enzyme Company (NEC)
  187. National Heart, Lung, and Blood Institute (NHLBI)
  188. National Institute of Allergy and Infectious Diseases (NIAID)
  189. National Institutes of Health Clinical Center
  190. NDB Healthcare
  191. Nebraska Cultures
  192. New Bellus
  193. NIZO
  194. Norax Supplements
  195. Northway BiotechPharma
  196. Novartis
  197. Novavax
  198. Novo Nordisk
  199. NOW Foods
  200. NuBiyota
  201. NUMAFERM
  202. NutraScience Labs
  203. Ology Bioservices
  204. Olon
  205. Orkila 
  206. Osel
  207. OxThera
  208. Panacea Biotec
  209. Paragon Bioservices (unit of Catalent Biologics)
  210. Paras Biopharmaceuticals Finland
  211. Pfizer
  212. Pfizer CentreOne
  213. Pharma-Zentrale
  214. Phi Therapeutics
  215. Pierre Fabre
  216. PiLeJe
  217. Polpharma Biologics
  218. Polymun Scientific
  219. Porton Biopharma
  220. Premas Biotech
  221. Probi
  222. ProbioFerm
  223. Probiotic Holdings
  224. Probiotical
  225. Probiotics Australia
  226. Probiotics International
  227. Probium
  228. Proventus Bioscience
  229. Pure Cultures
  230. PX’Therapeutics
  231. Qu Biologics
  232. Quay Pharma
  233. Quest Nutra Pharma
  234. Quorum Innovations
  235. Rebiotix (a subsidiary of Ferring Pharmaceuticals)
  236. Retron Probiotics
  237. Richter-Helm BioLogics
  238. Rise Therapeutics
  239. Ritter Pharmaceuticals
  240. Roche
  241. Sabinsa Europe (a subsidiary of Sami Labs)
  242. Sacco
  243. Sandoz
  244. Sarepta Therapeutics
  245. S-Biomedic
  246. SciBac
  247. Scientific Protein Laboratories
  248. Scil Proteins Pharma
  249. Scioto Biosciences
  250. Second Genome
  251. Seed Health
  252. Seres Therapeutics
  253. SFA Therapeutics
  254. SGL Probiotics
  255. Siam Bioscience
  256. SiliCycle
  257. Siolta Therapeutics
  258. Sirio Pharma
  259. SkinBioTherapeutics
  260. Snipr Biome
  261. Specialty Enzymes & Probiotics
  262. Stelis BioSource™
  263. Symberix
  264. Symbiotix Biotherapies
  265. Syngen Biotech
  266. Syngene Interntional
  267. Synlogic (acquired by Mirna Therapeutics)
  268. Synthetic Biologics
  269. Takeda Pharmaceutical
  270. TargEDys
  271. TARON Solutions
  272. Teva Pharmaceutical
  273. The Native Antigen
  274. Therapure BioPharma
  275. Thermo Fisher Scientific
  276. THT: probiotics and starter cultures
  277. Tokyo Chemical Industry 
  278. Touchlight Genetics
  279. Trayer Biotherapeutics
  280. TRU-ID
  281. UAS Labs
  282. Unique Biotech
  283. University of California
  284. University of Liverpool
  285. University of Oxford
  286. University of Pennsylvania
  287. University of Pittsburgh
  288. Vaiomer
  289. Vedanta Biosciences (a subsidiary of PureTech Health)
  290. VGXI
  291. Virun Nutra-Biosciences
  292. VITA-gen Laboratories
  293. Vitakem
  294. ViThera Pharmaceuticals
  295. VxP Biologics
  296. WACKER Biotech
  297. Waisman Biomanufacturing
  298. Washington University School of Medicine
  299. Weizmann Institute of Science
  300. Winclove Probiotics
  301. World Health Organization (WHO)
  302. WuXi Biologics
  303. Xycrobe Therapeutics (a subsidiary of Crown Laboratories)
  304. Yakult Honsha
  305. Zeta Farmaceutici
  306. Zhejiang Hisun Pharmaceutical
  307. Zytex

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com